First Time Loading...

Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 1.76 USD 0.57% Market Closed
Updated: Jul 27, 2024
Have any thoughts about
Compugen Ltd?
Write Note

Intrinsic Value

CGEN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. [ Read More ]

The intrinsic value of one CGEN stock under the Base Case scenario is 1.94 USD. Compared to the current market price of 1.76 USD, Compugen Ltd is Undervalued by 9%.

Key Points:
CGEN Intrinsic Value
Base Case
1.94 USD
Undervaluation 9%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Compugen Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CGEN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Compugen Ltd

Current Assets 105.6m
Cash & Short-Term Investments 101.3m
Receivables 4.3m
Non-Current Assets 8.1m
Long-Term Investments 3m
PP&E 4.2m
Other Non-Current Assets 934k
Current Liabilities 24.6m
Accounts Payable 13.4m
Accrued Liabilities 441k
Other Current Liabilities 10.8m
Non-Current Liabilities 29.4m
Other Non-Current Liabilities 29.4m
Efficiency

Earnings Waterfall
Compugen Ltd

Revenue
36m USD
Cost of Revenue
-4.1m USD
Gross Profit
31.9m USD
Operating Expenses
-43.3m USD
Operating Income
-11.3m USD
Other Expenses
-5.3m USD
Net Income
-16.7m USD

Free Cash Flow Analysis
Compugen Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CGEN Profitability Score
Profitability Due Diligence

Compugen Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROIC
Positive Gross Profit
Exceptional 1-Year Revenue Growth
36/100
Profitability
Score

Compugen Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

CGEN Solvency Score
Solvency Due Diligence

Compugen Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Average Altman Z-Score
65/100
Solvency
Score

Compugen Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CGEN Price Targets Summary
Compugen Ltd

Wall Street analysts forecast CGEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CGEN is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 7.35 USD.

Lowest
Price Target
4.04 USD
130% Upside
Average
Price Target
5.1 USD
190% Upside
Highest
Price Target
7.35 USD
318% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CGEN?

Click here to dive deeper.

Competitive Landscape

Price Appreciation

CGEN Price
Compugen Ltd

1M 1M
+0%
6M 6M
-28%
1Y 1Y
+71%
3Y 3Y
-72%
5Y 5Y
-46%
10Y 10Y
-79%
Annual Price Range
1.76
52w Low
0.53
52w High
2.95
Price Metrics
Average Annual Return 12.41%
Standard Deviation of Annual Returns 100.64%
Max Drawdown -97%
Shares Statistics
Market Capitalization 157.6m USD
Shares Outstanding 89 530 200
Percentage of Shares Shorted 2.03%

CGEN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Compugen Ltd Logo
Compugen Ltd

Country

Israel

Industry

Life Sciences Tools & Services

Market Cap

157.6m USD

Dividend Yield

0%

Description

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Contact

Holon
Azrieli Center, 26 Harokmim St. Bldg D
+97237658585.0
http://www.cgen.com/

IPO

2000-08-01

Employees

73

Officers

CEO, President & Director
Dr. Anat Cohen-Dayag Ph.D.
Senior Vice President of Technology Innovation
Dr. Zurit Levine Ph.D.
Vice President of Preclinical Development
Dr. Pierre Ferre Ph.D.
Chief Financial Officer
Mr. Alberto Sessa
Chief Scientific Officer
Dr. Eran Ophir Ph.D.
Head of Investor Relations & Corporate Communications
Ms. Yvonne Naughton
Show More
General Counsel & Corporate Secretary
Mr. Eran Ben Dor
Vice President of Human Resources
Ms. Dorit Amitay
Senior VP & Senior Advisor of Data and Informatics Solutions
Dr. Yaron Turpaz M.B.A., Ph.D.
Vice President Research and Discovery
Rivka Schwartz
Show Less

See Also

Discover More
What is the Intrinsic Value of one CGEN stock?

The intrinsic value of one CGEN stock under the Base Case scenario is 1.94 USD.

Is CGEN stock undervalued or overvalued?

Compared to the current market price of 1.76 USD, Compugen Ltd is Undervalued by 9%.